Viz.ai, Inc.

Viz.ai is a leading artificial intelligence (AI) powered healthcare company focused on improving patient outcomes through accelerated care coordination and clinical workflow solutions. Founded in 2016 by Dr. Chris Mansi and Dr. David Golan, the company's mission is to increase access to life-saving treatments by reducing systemic delays in healthcare. Headquartered in San Francisco, California, Viz.ai leverages advanced technology to transform how medical decisions are made and care is delivered.

The core of Viz.ai's offering is the Viz.ai One platform, which integrates over 50 FDA-cleared AI algorithms to analyze medical imaging data, including CT scans, EKGs, and echocardiograms. This platform provides real-time insights and automated assessments, streamlining diagnosis and treatment pathways. The company offers specialized suites such as Viz Neuro Suite for neurovascular diseases, Viz Vascular Suite for conditions like pulmonary embolism, Viz Cardio Suite for cardiac issues, Viz Trauma Suite, and Viz Radiology Suite. Viz.ai serves a broad market, including hospitals, health systems, and clinical specialists, and also collaborates with pharmaceutical and medical device companies through its Viz Life Sciences division.

Viz.ai has achieved significant market penetration, with its platform deployed in nearly 2,000 hospitals across the United States and Europe, covering over 230 million lives. In March 2024, Michael Herring was appointed as Chief Financial Officer, joining co-founder and CEO Dr. Chris Mansi in leadership. The company has seen substantial growth, doubling its life sciences business with 13 strategic partnerships, and achieved profitability in its healthcare business in 2025. Viz.ai has been recognized in TIME's World's Top Health Companies 2025, and Dr. Mansi was named one of TIME Magazine's 100 Most Influential People in AI in 2024, underscoring its impact and innovative standing in the healthcare AI landscape.